1. 550PEvaluation of the sensitivity of RAS mutation detection of the Idylla platform in comparison to the OncoBEAM RAS CRC assay. (23rd October 2018) Authors: Vivancos, A; Aranda Aguilar, E; Benavides, M; Elez Fernandez, E; Toledano, M; Alvarez, M; Diaz Rubio, E; Gómez-España, A; Garcia-Barberan, V; Chica-Parrao, M R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. (14th November 2017) Authors: Abad, A; Martínez-Balibrea, E; Viéitez, J M; Alonso-Orduña, V; García Alfonso, P; Manzano, J L; Massutí, B; Benavides, M; Carrato, A; Zanui, M; Gallego, J; Grávalos, C; Conde, V; Provencio, M; Valladares-Ayerbes, M; Salazar, R; Sastre, J; Montagut, C; Rivera, F; Aranda, E Journal: Annals of oncology Issue: Volume 29:Number 2(2018) Page Start: 439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. O-026Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). (2nd July 2019) Authors: Argiles, G; Margalef, N Mulet; Valladares-Ayerbes, M; de Prado, J Vieitez; Grávalos, C; Alfonso, P García; Santos, C; Tobeña, M; Sastre, J; Benavides, M; Cano, T; Loupakis, F; Garrote, M Rodriguez; Rivera, F; Goldberg, R; Falcone, A; Bennouna, J; Ciardiello, F; Tabernero, J; Aranda, E Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗